A randomized controlled trial of cognitive-behavior therapy for persistent symptoms in schizophrenia: a five-year follow-up. by Turkington, Douglas et al.
Nur, U; Rachet, B; Parmar, MK; Sydes, MR; Cooper, N; Stenning, S;
Read, G; Oliver, T; Mason, M; Coleman, MP (2012) Socio-economic
inequalities in testicular cancer survival within two clinical studies.
Cancer epidemiology, 36 (2). pp. 217-21. ISSN 1877-7821
Downloaded from: http://researchonline.lshtm.ac.uk/232/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
1 
 
Socio-economic inequalities in testicular cancer survival within two clinical studies 
 
Ula Nur1, Bernard Rachet1, Mahesh KB Parmar2, Mathew R Sydes2, Nicola Cooper3 
Sally Stenning2, Graham Read4, Tim Oliver5, Malcolm Mason6, Michel P Coleman1 
 
1 Cancer Research UK Cancer Survival Group, Non-Communicable Disease 
Epidemiology Unit, London School of Hygiene and Tropical Medicine, Keppel St, 
London WC1E 7HT, UK 
2 Cancer Group, MRC Clinical Trials Unit, Aviation House, 125 Kingsway, London  
WC2B 6NH 
3 National Cancer Intelligence Centre, Social and Health Analysis and Reporting 
Division, Office for National Statistics, (Room FG/114) 1 Myddelton Street, 
London EC1R 1UW, UK 
4 Royal Preston Hospital, Preston, PR2 9HT 
5 Barts cancer institute, Barts and the London School of Medicine, Queen Mary 
University London, EC1M 6BQ 
6 Cardiff University School of Medicine, Cardiff CF14 4XN   
 
Funding: Cancer Research UK, UK Medical Research Council funds (MP, MS, SS). 
 
Length: 2,348 words, 2 Tables, 2 Figure, 19 references. 
 
Correspondence 
Dr Ula Nur PhD, Lecturer in Cancer Survival, Cancer Research UK Cancer Survival 
Group, Department of Non-Communicable Disease Epidemiology, London School of 
Hygiene and Tropical Medicine, Keppel St, London WC1E 7HT, UK, +44 20 7927 
2091, F + 44 20 7436 4230, ula.nur@lshtm.ac.uk 
2 
 
ABSTRACT 
Background: Testicular cancer is the most common cancer in men under 35 years of 
age, and has the highest survival for adult male malignancies. Despite the fact that 
survival is very high, there is evidence that survival differs between socio-economic 
groups.  
Methods: We analyzed survival patterns for 1 606 testicular cancer patients diagnosed 
during 1984-2001 and recruited to one of two clinical studies. The first was a 
surveillance study to determine relapse-free survival after orchidectomy in 865 patients 
with stage I nonseminomatous germ-cell testicular cancer diagnosed during 1984-1991 
(TE04). The second study was a trial in which 1 174 men with stage I seminomatous 
germ-cell tumours were randomised to receive radiotherapy or one injection of 
carboplatin between 1996 and 2001, (TE19). The number of men available for analysis 
from these two studies was 578 and 1 028 respectively. We followed these patients up 
for their vital status, and assigned them an ecological measure of deprivation. Crude and 
relative survival were estimated at 5 and 10 years by socio-economic deprivation.  
Results: No significant socio-economic gradient was seen: 1.3% (95% CI -0.3% to 
3.1%) at 5 years and 2.1% (95% CI -0.5% to 4.7%) at 10 years.  
CONCLUSION: We conclude that, given equal treatment at a given stage of disease, 
survival from testicular cancer does not depend on socio-economic status. This suggests 
that the socio-economic gradient in testicular cancer survival in the general population 
is more likely to be attributable to health care system factors than to personal or socio-
economic factors in the men themselves.  
 
 
Keywords: cancer survival, deprivation, cancer registries, testicular cancer, relapse, 
carboplatin.  
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INTRODUCTION 
Cancer survival in England and Wales differs between socio-economic groups for most 
adult cancers [1], and in many populations [2]. 5-year survival for adults from deprived 
areas was significantly lower than that of patients from affluent areas for most of the 
major 47 cancers [3]. Despite the fact that survival from testicular cancer is high, socio-
economic differences in survival were demonstrated for men diagnosed in England and 
Wales during the early 1970s [3], after adjustment for background mortality with life 
tables specific for each socio-economic group. Further evidence of socio-economic 
inequalities was confirmed in men with testicular cancer diagnosed during the late 
1990s [4]. Differences in stage at diagnosis and access to treatment partly explain the 
socio-economic inequalities in cancer survival, but it is less clear why these differences 
arise [5].  
 
Patients who take part in cohort studies or clinical trials fit strictly defined eligibility 
criteria and receive the same mandated treatment and follow-up, with close adherence to 
the study protocol. One would not expect the treatment received within each trial arm to 
vary between socio-economic groups, because the socio-economic status of the men 
was unknown at recruitment to the cohort study or randomisation in the trial.  
 
The aim of this study was to measure any socio-economic differences in survival among 
men with testicular cancer recruited to two clinical studies. A socio-economic survival 
gradient within these study populations would imply that biological factors explain the 
survival gradient in the general population, while the absence of such a gradient would 
imply that access to treatment or other healthcare system factors are more likely to 
explain the inequalities in survival in the general population. 
 
 
MATERIALS AND METHODS 
The Medical Research Council (MRC) Clinical Trials Unit (CTU, formerly the MRC 
Cancer Trials Office) conducted the original testicular cancer studies, TE04 and TE19 
(ISRCTN27163214).  
 
The TE04 was a prospective single-arm cohort study which aimed to determine the rate 
of relapse and its predictive histological criteria among patients treated by orchidectomy 
alone for stage I nonseminomatous germ-cell testicular tumour (NSGCT). The patients 
were recruited from 16 United Kingdom centres and one Norwegian centre between 
January 1984 and October 1991, and attended follow-up assessment at monthly 
intervals for the first year, every 2 months for the second year and every 3 months for 
the third year, and regularly thereafter. The MRC Clinical Trials Unit constructed a 
dataset on a total of 865 men, of which 768 were registered in England or Wales 
between January 1984 and October 1991. Overseas patients and patients resident in 
Scotland were excluded because no information on their postcode of residence was 
available. Results for the first 396 men recruited between January 1984 and October 
1987 confirmed the effectiveness of surveillance for the management of stage 1 NSGCT 
and identified a group of patients with high risk of relapse on histological criteria [6].  
 
In the TE19 trial, 1 477 patients from 70 hospitals in 14 countries with stage 1 
seminomatous germ-cell tumours were randomly assigned by the MRC Clinical Trials 
Unit or the EORTC (European Organisation for Research and Treatment of Cancer) to 
receive either radiotherapy or one injection of carboplatin following orchidectomy. 
Relapse-free survival rates were compared between the trial arms. Carboplatin proved to 
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be an effective adjuvant treatment and similar in outcome to radiotherapy [7] with 
respect to relapse rates. All non-UK patients were excluded, and a final dataset on 1 174 
men of whom 1 112 were resident in England and Wales was prepared for analysis. 
 
The Office for National Statistics (ONS) flagged patients on the National Health Service 
Central Register and provided information on their vital status (alive, dead, emigrated or 
lost to follow-up) up to 31 December 2008. The ONS also provided the postcode of the 
patient’s residence at diagnosis, from which they were assigned to one of five 
deprivation categories (from 1 ‘most affluent’ to 5 ‘most deprived’). Individual 
information was not available on the socio-economic status of these cancer patients; 
instead the Carstairs index [8], an ecological measure of deprivation based on four 
census-derived variables at the level of the census enumeration district (ED), was used 
to assign a deprivation category to patients diagnosed 1984-1995. The deprivation 
category was based on the 1981 census for men diagnosed 1984-1985 and 1991 census 
for men diagnosed 1986-1995. One of the four Carstairs components was changed in the 
2001 census, and therefore was not comparable to that used in 1981 and 1991. The ONS 
introduced the Indices of Multiple Deprivation (IMD) in 2000. This new index is mostly 
based on routine administrative data and is regularly updated. It has already been shown 
that the choice of the deprivation index has little impact on the deprivation gap [9]. The 
ONS also changed the geographic level enumeration district (ED-mean population 450) 
to the larger but more socially homogenous level of the Lower Super-Output Areas 
(LSOA) (mean population 1 500) in 2001. For those diagnosed during 1996-2001, 
deprivation categories were defined from the income domain score of the (IMD2004) 
[10] using administrative data of the 34 378 LSOAs in England. For patients in Wales, 
we used the equivalent Welsh index [11].  
 
Of the 1 880 patients resident in England or Wales initially considered for analysis, a 
further 274 patients (190 from TE04 and 84 from TE19) were excluded, either because 
their postcode was missing, which meant that their socio-economic status could not be 
defined, or because their vital status was unknown i.e. patients who were not known to 
be dead, but whose records could not be traced to enable ‘flagging’ by the end of 
follow-up time, or because the record failed ONS validity checks i.e. one of the 
mandatory fields required by ONS was not correct (Figure 1).  
 
Patients consented to join both studies. Multi-Centre Research Ethics Committee 
approval for this additional use of the data was obtained from West Midlands MREC for 
TE19 in 2006 and the MREC for Wales for TE04 in 2005. Approval was obtained for 
this study from the Ethics Committee of the London School of Hygiene and Tropical 
Medicine.  
 
 
 
Statistical analyses 
The men were followed up for at least five years to the end of 2008, the last year for 
which vital status was available through ONS. Survival time was calculated as the time 
between the date of diagnosis and the earliest of the date of death or 31 December 2008. 
Relative survival was estimated using the maximum-likelihood approach for individual 
data [12]. Relative survival is the ratio of the observed probability of survival in a 
cancer population to the expected probability of survival (background) in the general 
population with the same age, sex, geographic area, calendar period, and deprivation. 
This approach does not rely on the accurate reporting of cause of death, and is widely 
used in estimating population based survival. We report relative survival at 5 and 10 
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years by deprivation category. The background mortality varies widely by age, sex, 
socioeconomic group and Government Office Region (GOR). For 1981-2005, 
background mortality was represented by complete life tables defined by sex, single 
year of age, calendar year, deprivation category and GOR [13]. Because of the 
unavailability of life tables by socioeconomic group and GOR for the years after 2005, 
the 2005 life tables were used for deaths that occurred during 2006-2008.  
 
Socio-economic inequality in survival (the ‘deprivation gap’) was quantified as the 
fitted difference (%) between relative survival in the most deprived and most affluent 
groups in the study population, estimated with variance-weighted linear regression [14] 
applied to all the deprivation-specific survival estimates. We describe the deprivation 
gap as negative if relative survival is lower in the most deprived group. We then 
compared this gap with that in the general population of England for men diagnosed 
with testicular cancer during 1984-2001. 
 
 
RESULTS 
The distribution of socio-economic status among the 1 606 men included in the analysis 
from the two studies was strikingly similar to that of men with testicular cancer in the 
general population of England and Wales: 16% in the most deprived group and 21-22% 
in each of the other four groups (Table 1). The distribution by deprivation was also 
similar in both studies. Around 70% of men were less than 40 years of age at diagnosis, 
almost 20% aged 40-49, and only around 10% were aged 50 or over. The distribution by 
deprivation and age was very similar to that of all men diagnosed with testicular cancer 
in England and Wales during 1984-2001.  
 
Relative survival in the study population was high and similar across the five 
deprivation groups. This ranged from 100% to 97% at 5 years, and from 100% to 96% 
at 10 years (Table 2). The fitted difference in survival between the most deprived and 
the most affluent groups in the combined study population was 1.4% five years after 
diagnosis and 2.2% ten years after diagnosis, meaning that the more deprived groups 
tended to have a higher survival than the ‘most affluent’ (Table 2, Figure 2). Neither 
result was statistically significant (Table 2). By contrast, survival was lower among the 
more deprived groups in the general population of England and Wales for men 
diagnosed during 1984-2001. The gap remained unchanged at -3.1% (95% CI -4.0% to -
2.1%) at 5 years and -3.1% (95% CI -4.2% to -2.1%) at 10 years (Table 2).  
 
 
CONCLUSION 
Survival from testicular cancer was the highest among all malignancies in adult males in 
England and Wales throughout the period 1986-1999, exceeding 90% ten years after 
diagnosis [4]. A significant deprivation gap in survival has been observed in the general 
population since the 1970s, although the gap decreased substantially from 13% in the 
1970s to around 3% during 1984-2001. This decrease in the deprivation gap appears to 
reflect a ‘ceiling’ effect, following the substantial improvements in survival associated 
with the introduction of platinum-based chemotherapy in the 1970s, in that there is little 
further room for increase in survival among men in the most affluent group. By contrast, 
in these two studies, affluent patients did not do better than the most deprived, and 
survival (as expected for patients diagnosed with stage I disease) exceeded 95% even 
ten years after diagnosis. A recent review of patients whose management was complex 
(Oliver RTD,   Queen Mary University London) suggests that much of the remaining 
risk of death relates to the wide variety of clinicians to whom atypical metastatic 
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manifestations of this disease can present, ranging from orthopaedic surgeons, 
gastroenterologists, thoracic surgeons, endocrinologists, neurologists and 
neurosurgeons, none of whom is routinely involved in the Multidisciplinary Team 
management of testicular cancer [15]. If improvement is to be made in their 
management, it may be necessary to develop some form of annual confidential review 
of deaths, as occurs with Maternal Mortality to give a global feedback where failure is 
occurring, as they often reveal problems involving four or more different clinicians. 
 
Because of the excellent prognosis of patients with testicular cancer and the relative 
youth of the testicular cancer patients, only 72 deaths occurred among the 1 606 patients 
included for analysis, all followed up for at least 5 years. The small number of deaths 
within each deprivation group was the major limitation of this study. This prohibited the 
estimation of relative survival and its confidence intervals with the available statistical 
methods for some of the deprivation categories with either none or very few deaths. All 
the men in the two studies had stage 1 testicular cancer.  
 
Detailed information was available on treatment, socio-economic deprivation and vital 
status on 1 606 patients in one cohort study and one randomised controlled trial. 
Allocation of patients to treatment in clinical studies and randomisation of patients in 
randomised trials ensures that patients follow the treatment policy stated in the study 
protocol, regardless of their socio-economic status. There was also no difference 
between the two trials in prognosis (all patients included with stage 1 testicular cancer), 
or by treatment within each of the analysed studies. In the TE04 study, all patients were 
treated by orchidectomy only prior to relapse, whereas in the trial (TE19), no evidence 
was found in favour of a difference in outcome between carboplatin and radiotherapy 
[7].  
 
Both five-year and ten-year survival were higher among patients recruited to one of the 
two studies than among testicular cancer patients in England and Wales in the same 
period. This is an expected finding, in part because cancer patients taking part in clinical 
trials generally have higher survival than cancer patients in the general population [16, 
17], and in part because only patients with stage 1 tumour were recruited in both 
studies. In a consecutive case study of 550 men with testicular cancer seen at a tertiary 
referral centre, between half and a quarter of testicular cancer patients had metastatic 
disease and there was clear reduction of the number of patients presenting with more 
advanced disease overtime  [18]. 
  
In a setting similar to this study, no difference in survival was found between rich and 
poor colorectal cancer patients who took part in a large clinical trial [19], when patients 
were given equal protocol-based treatment. One could argue that the inclusion of 
patients in clinical studies may lead to selection bias, and that fewer patients are 
included from deprived areas, perhaps due to severe co-morbidity. However, the 
distribution of the study patients by deprivation quintiles was very similar to that seen 
among all cancer patients in the general population. Moreover, information on socio-
economic status was not known to the investigators at the time of entry to the study; it 
was only derived later from the postcode of the patients at time of diagnosis. It is 
possible that the deprivation gap observed in the general population is mostly due to 
differential distribution of tumour stage by deprivation, with higher proportion of the 
advanced stage 3 disease among the more deprived patients, while only patients with 
stage 1 were included in these studies. However, there has been continuous 
improvement in survival since the 1980s, both among elderly and deprived patients 
while chemotherapy treatment remained largely the same. A likely explanation is that 
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more patients are diagnosed at the early stage due to greater awareness of testicular 
cancer [20]. Several UK centres have also reported fewer patients presenting with 
advanced disease [21]. Another potential explanation of the ‘deprivation gap’ seen in 
the general population could be explained by deprived patients presenting with many 
comorbid conditions that could affect cancer outcome [22], an example of such more 
atypical advanced presentations in situations of social deprivation was reported by 
Mulatero, et al. [23]. However in the context of the relatively young patient population 
(around 70% less than 40 years of age) co-morbidity seems like a less probable 
explanation. 
 
Our findings, based on data collected prospectively in two national clinical studies 
suggest, that given equal treatment, survival from testicular cancer, at least for stage I 
disease, which comprise more than half of all cases, with which high percentage of 
patients are diagnosed, does not depend on socio-economic deprivation. This implies 
that the deprivation gap seen in the general population is more likely to be due to 
differences in access to treatment than to patient related factors.  
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Figures 
Figure 1 
Distribution of patients in the two clinical studies (TE04 and TE19). 
Figure 2 
Relative survival (%) up to ten years by deprivation category, in the study and the 
general population of England and Wales (1984-2001). 
Tables 
Table 1 
Number (%) of men with testicular cancer by deprivation group 
Table 2 
Relative survival (%) by deprivation category, and deprivation gap (%) at five and ten 
years after diagnosis 
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Table 1: Number (%) of men with testicular cancer by deprivation group 
(a) Study population (1984-2001) 
Deprivation category 
No of patients Most affluent 2 3 4 Most deprived 
No. % No. % No. % No. % No. % No. % 
 
No. of patients  349 21.7 330 20.5 340 21.2 337 21.0 250 15.6 1 606 100.0 
 
 
Trial 
 
TE04 131 22.7 124 21.5 128 22.1 112 19.4 83 14.4 578 36.0 
 
TE19 218 21.2 206 20.0 212 20.6 225 21.9 167 16.2 1 028 64.0 
 
 
Age at diagnosis 
Less than 40 236 21.0 214 19.0 248 22.0 248 22.0 179 15.9 1 125 70.0 
 
40-49 69 21.0 83 25.2 63 19.1 67 20.4 47 14.3 329 20.5 
 
50 and over 44 28.9 33 21.7 29 19.1 22 14.5 24 15.8 152 9.5 
 
(b) General population of England and Wales (1984-2001) 
 
No. of patients  5 313 21.9 4 932 20.3 4 983 20.5 4 958 20.4 4 078 16.8 24 264 100.0 
 
 
Age  
 
Less than 40 3 327 20.2 3 268 19.8 3 428 20.8 3 529 21.4 2 939 17.8 16 491 68.0 
 
40-49 1 221 26.2 1 016 21.8 915 19.6 856 18.4 651 14.0 4 659 19.2 
 
50 and over 765 24.6 648 20.8 640 20.6 573 18.4 488 15.7 3 114 12.8 
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Table 2: Relative survival (%) by deprivation category, and deprivation gap (%) at five and ten years after diagnosis 
Five-year survival  Ten-year survival  
Crude survival Relative survival Crude survival Relative survival 
95 % CI 95 % CI 95 % CI 95 % CI 
Deprivation Patients Deaths Lower Upper Lower Upper Deaths Lower Upper Lower Upper 
(a) Study populations (1984-2001) 
Most affluent 349 8 97.7 95.5 98.8 98.8 95.8 99.7 11 96.8 94.4 98.2 98.2 95.2 99.3 
2 330 12 96.4 93.7 97.9 97.3 94.5 98.7 17 94.6 91.4 96.6 96.4 92.9 98.2 
3 340 1 99.7 97.9 100.0 100.0 − − 7 97.7 95.1 98.9 99.2 93.3 99.9 
4 337 1 99.7 97.9 100.0 100.0 100.0 − 5 98.3 95.8 99.3 99.5 90.4 100.0 
Most deprived 250 4 98.4 95.8 99.4 99.8 − 100.0 7 97.0 93.7 98.6 99.8 − 100.0 
Deprivation gap 1.4 2.2 
(b) General population of England and Wales (1984-2001) 
Most affluent 5 313 350 93.4 92.7 94.0 95.3 94.6 95.9 459 91.1 90.3 91.9 94.8 94.0 95.4 
2 4 932 351 92.9 92.1 93.5 94.9 94.2 95.6 448 90.7 89.8 91.5 94.5 93.7 95.2 
3 4 983 423 91.5 90.7 92.2 94.2 93.4 94.9 540 88.9 87.9 89.7 93.3 92.4 94.1 
4 4 958 441 91.1 90.2 91.8 93.8 93.0 94.5 567 88.1 87.2 89.0 93.3 92.4 94.1 
Most deprived 4 078 469 88.4 87.4 89.4 91.6 90.6 92.5 577 85.4 84.3 86.5 91.1 90.0 92.1 
Deprivation gap -3.1* -3.1* 
*Statistically significant at 1%. 
− unavailable estimates due to small number of deaths in the specific time interval 
 
 
